Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Multiplicom receives €200,000 grant for novel non-invasive pre-natal test
IWT grant to support development of early aneuploidy detection during pregnancy

Niel, June 6th, 2012

Today Multiplicom, a molecular diagnostics company specializing in the design, development, production and commercialization of innovative molecular genetic tests based on massively parallel sequencing, announces that it has been awarded a €200,000 ($260,000) grant from the Flemish agency for Innovation by Science and Technology (IWT). The grant is intended to support the development of a novel test for genetic abnormalities during pregnancy that needs only a blood sample, in contrast to the invasive screening methods in use today. The test will be based on Multiplicom’s proprietary MASTR (Multiplex Amplification of Specific Targets for Resequencing) workflow.

Dr. Dirk Pollet, CEO of Multiplicom, said: “This grant is a strong endorsement of our MASTR technology. It will allow Multiplicom to develop a new assay that will help physicians and patients enhance prenatal medical care while cutting costs. In the future, we see this test entirely replacing current invasive techniques.”

The test, a single tube multiplex PCR reaction starting from fetal DNA isolated from the mother’s blood, allows the identification of copy number variations (or ‘aneuploidies’) of chromosomes 21, 18, 13, X and Y. Such variations cause genetic diseases like Down’s syndrome, Edward’s syndrome, Patau syndrome, triple X syndrome and Klinefelter’s syndrome.

Multiplicom’s innovative non-invasive aneuploidy testing – NIAT – is a novel approach that aims to replace the 250,000 invasive procedures such as amniocentesis and chorionic villus sampling performed annually in Europe. These procedures are time consuming and carry a significant risk of complications during pregnancy. NIAT is not only rapid and safe but is designed to have predictive power superior to that of conventional prenatal testing methods.

Subsequent validation studies will be conducted in close collaboration with hospitals throughout Europe. Multiplicom aims to make the test available to all accredited genetics labs as part of its drive to make personalized healthcare available to all.

Dr Dirk Pollet, CEO
+32 (0) 3 289 14 00
Nicole Yost / Jayne Crook

College Hill Life Sciences
+44 (0) 207 866 7855 / 7862 /

About Multiplicom
Multiplicom produces molecular diagnostic kits that enable clinical laboratories to perform
affordable testing for personalized medicine. The company was created in 2011 as a spin-off by
the University of Antwerp and VIB. Multiplicom develops, manufactures and commercializes
leading-edge and easy-to-use genetic test kits based on the latest molecular diagnostic
technologies. The successful introduction of its kits in medical genetics labs proves they are the
solution to an increasing demand for nucleic acid based testing that is driven by the scientific
evidence that links genetic information to health and disease.

Publisher Contact Information:

+32 (0) 3 289 14 00

Company profile of Multiplicom
Past press releases of Multiplicom.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Nov 8N/AOther Computers & Electronics
Nov 5€2.1MAudio/Video
Nov 5€5.2MOther Computers & Electronics
Nov 5€0.4MInternet services
Nov 5€1.3MSecurity
Nov 5€1.5MAudio/Video

For information on Europe's most extensive database on technology funding click here!


Press Releases

Sep 30
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.